NASDAQ moves to delist Lyra Therapeutics over public shell concerns Feb 6, 2026 04:14PM
Lyra Therapeutics suspends lead drug development, cuts workforce Jan 12, 2026 07:03AM
Lyra Therapeutics (LYRA) Halted, News Pending Jan 12, 2026 06:56AM
Lyra Therapeutics (LYRA) Misses Q3 EPS by 338c Nov 13, 2025 06:25AM
BTIG Reiterates Neutral Rating on Lyra Therapeutics (LYRA) Nov 13, 2025 02:03AM


Aug 12, 2025 04:01PM Lyra Therapeutics (LYRA) Misses Q2 EPS by 534c
Aug 1, 2025 04:05PM Lyra Therapeutics (LYRA) Announces Departure of Chairman Waksal
Jun 27, 2025 08:00AM Lyra Therapeutics (LYRA) Announces $15M Offering and Concurrent Private Placement
Jun 10, 2025 06:04AM Lyra Therapeutics (LYRA) PT Raised to $16 at H.C. Wainwright
Jun 2, 2025 04:32PM BTIG Reiterates Neutral Rating on Lyra Therapeutics (LYRA)
Jun 2, 2025 10:25AM Lyra Therapeutics (LYRA) PT Raised to $30 at Jefferies
Jun 2, 2025 07:01AM Lyra Therapeutics (LYRA) Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of
May 6, 2025 05:46PM Lyra Therapeutics (LYRA) Misses Q1 EPS by 1c
Nov 12, 2024 04:05PM Lyra Therapeutics (LYRA) Tops Q3 EPS by 4c
Oct 15, 2024 07:00AM Lyra Therapeutics (LYRA) Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Aug 15, 2024 06:44AM H.C. Wainwright Reiterates Neutral Rating on Lyra Therapeutics (LYRA)
Aug 14, 2024 04:35PM Lyra Therapeutics (LYRA) Misses Q2 EPS by 41c